focus -WSS

focus

author：knowledge 2025-09-27 15:20:59 - browse：9252

Senator Ron Wyden (D-OR) speaks with reporters in the Senate subway at the U.S. Capitol — Sen. Ron Wyden (D-Ore.) Drew Angerer/Getty Images

Senate Finance Committee members from both parties took aim Wednesday at insurance brokers that sell plans for large Medicare Advantage insurers.

Older adults at times have more than 100 plan options, and brokers help them choose the right one. But brokers can be incentivized by large insurance companies to aggressively sell plans that are a poor fit for the Medicare beneficiaries they’re supposed to help. Brokers also sometimes collect private information that they sell to multiple insurance companies. Those brokers tend to have a national scope, just like the large insurers they represent, compared to the independent, local brokers.

“They are big private marketing companies in the middle between seniors and their coverage,” Chairman Ron Wyden (D-Ore.) said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

explore

WSS

President Biden's budget: Here's what you might have missed

President Biden's budget: Here's what you might have missed

FDA advisers back CAR

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Readout Newsletter: Zepbound, Valneva's vaccine, and more

What is STAT's opinion section for?

hotspot

focus

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

FDA advisers back CAR

Cancer drug shortages should be causing more outrage

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Psychedelics group wrestles with new pharma identity

Medicare’s new pay boost for primary care is angering specialists

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: CAR

What does generative AI mean for health care? We asked experts

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Wikipedia

Publishing genetic code of viruses could cause disaster

Pushing for an NIH office for post

Carbon Health diabetes program, a test of data

First U.S. drug developed to treat liver disease MASH is approved

A letter from the executive editor: STAT UnitedHealth investigation

How state and local governments are sidelining science

hotspot

explore

knowledge

focus